Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product... see more

Current News (NDAQ:PMN)

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

GlobeNewswire December 18, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

GlobeNewswire December 10, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

GlobeNewswire December 1, 2025

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire December 1, 2025

ProMIS Neurosciences Announces Reverse Stock Split

GlobeNewswire November 24, 2025

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

GlobeNewswire November 12, 2025

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire November 3, 2025

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

GlobeNewswire October 22, 2025

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

RE:after hours

After hours Corporate Presentation copy and paste change the date. Only company in this high profile field supposedly sneaks in after...
FarmerBetsy - 9 hours ago

after hours

We must be close to a financing, low volume and price falling. Price is 7.70 after hours.
goldtech - 2 days ago

next CEO

Seems like Maria Corina Machado will be available, when Warma leaves after his next and greatest financing shortly after the warrant...
M101 - 6 days ago

2026 is here

This is the year we've been waiting for... for a long time. Happy 2026.  
Gbathat - December 31, 2025

RE:RE:Disgusting Manipulation

What AI drug platform success looks like in China, same time line as Promis but on another planet.  ingvc.com/en/news/qiming...
M101 - December 31, 2025

RE:Disgusting Manipulation

We can argue about Warma's role in it but the 25:1 suggests he at least recognized the selling could continue until the money runs...
M101 - December 31, 2025
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »

Podcasts